New Drugs and Pipeline Questioned as Keytruda LOE Looms

What happened

Merck faces a well-documented challenge: Keytruda's patent cliff (2028-2029) and Gardasil China inventory issues, with the company relying on new launches, cost restructuring, and aggressive M&A to cushion the blow. The Zacks article raises the same question that underpins the market's current wait-and-see stance—whether pipeline assets like Winrevair and Capvaxive can materially offset the expected $2.5B 2026 headwind from generics and IRA pricing. Filings confirm that management expects Keytruda sales to decline materially after 2028 and that Gardasil China shipments remain paused with no clear restart timeline, making the near-term revenue bridge unusually uncertain. While the company's balance sheet is solid (net debt/EBITDA 1.4x) and restructuring savings of ~$1.7B by 2027 are fully reinvested, the earnings base remains dangerously concentrated in a single drug facing a two-step LOE. The article adds no new data but underscores the persistent narrative that Merck's post-Keytruda strategy is still unproven, with any re-rating dependent on visible launch momentum and China vaccine normalization.

Implication

At 16.2x P/E, MRK prices in a flat 2026 but does not discount Keytruda's two-step decline. The next 6-12 months require proof that launches like Winrevair can scale and that the $2.5B headwind stays contained. Until then, the risk/reward is balanced; a re-rating above $135 would need acceleration in BD integration or a restart in Gardasil China shipments. Downside to $105 is possible if headwinds intensify or if management signals additional M&A is needed to fill the post-Keytruda gap.

Thesis delta

No shift. The article reinforces the existing wait rating; the core thesis remains unchanged—Merck's earnings power will transition as Keytruda erodes, and the next 6-9 months are a holding pattern. Any bullish or bearish catalyst is tied to observable milestones (PDUFA, China shipments, quarterly headwind updates).